Bridgeway Capital Management, LLC Immuneering Corp Transaction History
Bridgeway Capital Management, LLC
- $4.14 Billion
- Q2 2024
A detailed history of Bridgeway Capital Management, LLC transactions in Immuneering Corp stock. As of the latest transaction made, Bridgeway Capital Management, LLC holds 53,949 shares of IMRX stock, worth $143,504. This represents 0.0% of its overall portfolio holdings.
Number of Shares
53,949
Previous 114,049
52.7%
Holding current value
$143,504
Previous $329,000
79.03%
% of portfolio
0.0%
Previous 0.01%
Shares
4 transactions
Others Institutions Holding IMRX
# of Institutions
60Shares Held
9.65MCall Options Held
0Put Options Held
0-
Ken Griffin Citadel Advisors LLC | Chicago, Il1.88MShares$5.01 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.07MShares$2.85 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny953KShares$2.54 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD859KShares$2.29 Million0.0% of portfolio
-
Goldman Sachs Group Inc New York, NY742KShares$1.97 Million0.0% of portfolio
About Immuneering Corp
- Ticker IMRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,392,300
- Market Cap $70.2M
- Description
- Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to tr...